首页> 外文OA文献 >Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

【2h】

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

机译：来自开放标签的临床，患者报告和超声结果，在西班牙语患者中，在西班牙语患者中的12周观测研究，有或没有先前的抗TNF暴露的抗TNF关节炎

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Francisco J. Blanco; Esteban Rubio-Romero; Raimon Sanmartí; César Díaz-Torné; Pablo Talavera; Jochen Dunkel; Esperanza Naredo;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. [J] . Michael H Schiff, Johannes von Kempis, Ronald Goldblum, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014 ,第12期

机译：类风湿关节炎对TNF的继发性无反应者可通过转换为certolizumab pegol获得有效和安全的反应：一项IV期，随机，多中心，双盲，12周研究，然后进行12周开放标签研究。
2. LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS, WITH AND WITHOUT PRIOR ANTI-TNF EXPOSURE [J] . Kavanaugh A., Gladman D., van der Heijde D., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016 ,第7期

机译：在有和没有先发性抗TNF暴露的类风湿关节炎患者中，经过4年的西妥珠单抗治疗后，工作场所和家庭生产率的长期改善以及社会参与
3. CLINICAL RESPONSES AND IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ARE ASSOCIATED WITH INCREASED PRODUCTIVITY IN THE WORKPLACE AND AT HOME IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL [J] . Bykerk V. P., Emery P., Weinblatt M. E., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016 ,第7期

机译：在临床和在家中用Certolizumab PEG治疗的类风湿关节炎患者中，生产率的提高与生产效率的提高有关
4. Clinical studies of immunomodulatory activities of Yunzhi -Danshen in breast cancer and nasopharyngeal carcinoma patients, and Lingzhi-San Miao San in rheumatoid arthritis patients. [D] . Bao, Yixi. 2005

机译：云芝丹参对乳腺癌和鼻咽癌患者及类风湿关节炎灵芝三妙散的免疫调节活性的临床研究。
5. Clinical Ultrasound and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study [O] . Piercarlo Sarzi-Puttini, Emilio Filippucci, Silvano Adami, -1

机译：中度至重度类风湿性关节炎患者接受西妥昔单抗聚乙二醇化（甲氨蝶呤）治疗后的临床超声和可预测性结果：CZP-SPEED研究的52周结果
6. PMS66 Effect Of Certolizumab Pegol On Workplace And Household Productivity In United States Patients With Rheumatoid Arthritis With Or Without Prior Anti-Tnf Exposure: Results From The Predict Study [O] . Kavanaugh A., Mease P.J., Strand V., 2014

机译：PMS66塞妥珠单抗对美国类风湿性关节炎患者的工作场所和家庭生产力的影响（有或没有事先抗Tnf暴露）：预测研究的结果

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

著录项

相似文献

相关主题

期刊订阅